Literature DB >> 18958621

Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads.

Hitomi Sezaki1, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yuzo Miyakawa, Hiromitsu Kumada.   

Abstract

BACKGROUND: Response to treatment in patients with chronic hepatitis C, with reference to age and gender, has not been examined fully. AIM: The influence of gender and age on treatment with pegylated interferon (PEG-IFN) and ribavirin was evaluated in a retrospective study.
METHODS: PEG-IFN and ribavirin were given for 48 weeks to 179 men and 121 women infected with hepatitis C virus (HCV) of genotype 1b in high viral loads (>100 kIU/ml).
RESULTS: Sustained virological response at 24 weeks after treatment was poorer in women than men who were aged >or=50 years (22% vs 53%, P < 0.001). Among the patients aged >or=50 years who had received >or=80% of the doses of PEG-IFN, ribavirin, or both, women responded less often than men (26% vs 64%, P < 0.001; 33% vs 61%, P = 0.022; and 32% vs 63%, P = 0.016; respectively). In multivariate analysis, male gender, retention of indocyanine green, ribavirin dose and compliance with therapy increased sustained virological response.
CONCLUSIONS: Response to combined PEG-IFN and ribavirin is poorer in female than male patients with hepatitis C who are aged >or=50 years, irrespective of compliance with treatment. Low estrogen levels in older women could be responsible for their impaired response to PEG-IFN and ribavirin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18958621     DOI: 10.1007/s10620-008-0500-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  39 in total

1.  The scientific challenge of hepatitis C.

Authors:  J Cohen
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

Review 2.  Natural history of hepatitis C.

Authors:  A Alberti; L Chemello; L Benvegnù
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

3.  Characterization of estrogen receptor from human liver.

Authors:  G P Rossini; G M Baldini; E Villa; F Manenti
Journal:  Gastroenterology       Date:  1989-04       Impact factor: 22.682

Review 4.  Gynecomastia.

Authors:  G D Braunstein
Journal:  N Engl J Med       Date:  1993-02-18       Impact factor: 91.245

5.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.

Authors:  M Vogt; T Lang; G Frösner; C Klingler; A F Sendl; A Zeller; B Wiebecke; B Langer; H Meisner; J Hess
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

6.  Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.

Authors:  Chee-Kin Hui; Man-Fung Yuen; Erwin Sablon; Annie On-On Chan; Benjamin Chun-Yu Wong; Ching-Lung Lai
Journal:  J Infect Dis       Date:  2003-03-07       Impact factor: 5.226

7.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

8.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.

Authors:  Shintaro Takaki; Akihito Tsubota; Tetsuya Hosaka; Norio Akuta; Takashi Someya; Masahiro Kobayashi; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2004-07       Impact factor: 7.527

View more
  28 in total

Review 1.  Peginterferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Akihito Tsubota; Kiyotaka Fujise; Yoshihisa Namiki; Norio Tada
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.

Authors:  Itaru Ozeki; Jun Akaike; Yoshiyasu Karino; Tomohiro Arakawa; Yasuaki Kuwata; Takumi Ohmura; Takahiro Sato; Naohiro Kamiya; Ichimaro Yamada; Kazuaki Chayama; Hiromitsu Kumada; Joji Toyota
Journal:  J Gastroenterol       Date:  2011-05-10       Impact factor: 7.527

3.  Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.

Authors:  Akihito Tsubota; Noritomo Shimada; Hiroshi Abe; Kai Yoshizawa; Rie Agata; Yoko Yumoto; Makiko Ika; Yoshihisa Namiki; Keisuke Nagatsuma; Hiroshi Matsudaira; Kiyotaka Fujise; Norio Tada; Yoshio Aizawa
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

4.  Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.

Authors:  Mariko Kobayashi; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Yusuke Kawamura; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Kazuaki Chayama; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2012-03-23       Impact factor: 7.527

5.  Clinical characteristics of null responders to Peg-IFNα2b/ribavirin therapy for chronic hepatitis C.

Authors:  Hideyuki Suzuki; Satoru Kakizaki; Norio Horiguchi; Takeshi Ichikawa; Ken Sato; Hitoshi Takagi; Masatomo Mori
Journal:  World J Hepatol       Date:  2010-11-27

6.  Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.

Authors:  Masayuki Kurosaki; Naoya Sakamoto; Manabu Iwasaki; Minoru Sakamoto; Yoshiyuki Suzuki; Naoki Hiramatsu; Fuminaka Sugauchi; Hiroshi Yatsuhashi; Namiki Izumi
Journal:  J Gastroenterol       Date:  2010-09-10       Impact factor: 7.527

7.  Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C.

Authors:  Mosaburo Kainuma; Norihiro Furusyo; Eiji Kajiwara; Kazuhiro Takahashi; Hideyuki Nomura; Yuichi Tanabe; Takeaki Satoh; Toshihiro Maruyama; Makoto Nakamuta; Kazuhiro Kotoh; Koichi Azuma; Junya Shimono; Shinji Shimoda; Jun Hayashi
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

8.  Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score.

Authors:  Hirotoshi Ebinuma; Hidetsugu Saito; Shinichiro Tada; Nobuhiro Nakamoto; Tazuko Ohishi; Satoshi Tsunematsu; Naoki Kumagai; Kanji Tsuchimoto; Nobuhiro Tsukada; Yasutaka Inagaki; Yoshinori Horie; Masahiko Takahashi; Kazuhiro Atsukawa; Yukishige Okamura; Takanori Kanai; Toshifumi Hibi
Journal:  Hepatol Int       Date:  2011-09-10       Impact factor: 6.047

9.  Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection.

Authors:  A H Hashmi; N Ahmad; S Riaz; L Ali; S Siddiqi; K M Khan; A R Shakoori; A Mansoor
Journal:  Genes Immun       Date:  2014-06-05       Impact factor: 2.676

10.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.